Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

A novel off-the-shelf CAR NK therapy using logic gates has shown complete remissions in relapsed AML patients, according to ...

To date, there is no established treatment protocol for this condition ... Forecasting optimal treatments in ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian ...

GI Innovation, a South Korean biotech company, announced on May 13 that it has been selected as a semi-finalist in the XPRIZE ...

SENTI-202 is a first-in-class off-the-shelf CAR-NK cell therapy targeting CD33 and FLT3 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).

A global study suggests that using small molecule inhibitors followed by epigenetic modifiers may significantly improve ...

Senti Biosciences, Inc.’s SNTI share price has dipped by 6.26%, which has investors questioning if this is right time to buy.